Simpler, Less Expensive Test for Ulcer Bug

Publication
Article
OncologyONCOLOGY Vol 12 No 1
Volume 12
Issue 1

Researchers from the University of Wurzburg in Germany have determined that a simple antibody test may be as effective in detecting Helicobacter pylori infection as the more invasive procedures that are currently used. They reported their findings

Researchers from the University of Wurzburg in Germany have determined that a simple antibody test may be as effective in detecting Helicobacter pylori infection as the more invasive procedures that are currently used. They reported their findings in the December 1997 issue of the Journal of Clinical Microbiology.

In the study, the researchers compared the sensitivity of a test for Hpylori-specific immunoglobulin G (IgG) antibodies with the standard tests in clinical practice. The antibody test had a 98% sensitivity, correctly diagnosing 58 of the 59 patients diagnosed by standard methods.

“The current gold standard tests in clinical practice, endoscopy for histology and the rapid urease test, are limited by their relatively high costs and the need for invasive procedures,” say the researchers. “Determination of antibodies against H pylori presents a relatively simple diagnostic method, with kits that can be used to perform this method now...readily available from commercial sources.”

Helicobacter pylori is a bacterium that lives in the harsh acidic environment of the stomach. The cause of most duodenal ulcers and an estimated 70% to 80% of gastric ulcers, H pylori is considered to be a risk factor for stomach cancer. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Related Content